News & Updates

Show Multimedia Only

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Elevated expression of the factor H-related protein 1 (FHR-1) seems to be a risk factor for atherosclerotic cardiovascular disease (ACVD), a recent study has found.

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021 by

The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021 by

In-hospital mortality, but not stroke, is greater among patients presenting with acute aortic syndromes and atrial fibrillation (AF) than those without AF, a study has shown.

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021

Olive oil intake may lower CVD risk among people with obesity

03 Dec 2021

For individuals with obesity, olive oil intake can help reduce the risk of developing cardiovascular disease (CVD) by suppressing thrombin-induced platelet activation, a study reports.

Olive oil intake may lower CVD risk among people with obesity

03 Dec 2021

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021 by

Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021

Milvexian prevents VTE after knee arthroplasty, bleeding risk low

02 Dec 2021 by

Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.

Milvexian prevents VTE after knee arthroplasty, bleeding risk low

02 Dec 2021

Does statin affect performance of PSA screening?

02 Dec 2021 by

Prostate-specific antigen (PSA) screening was associated with similar decrease in incidence of advanced prostate cancer (PCa) among statin users vs nonusers, but less detection of low-grade localized tumours in the former than the latter — indicating that statin does not compromise the benefits of PSA-based screening while also conferring the benefit of less overdiagnosis of low-risk tumours.

Does statin affect performance of PSA screening?

02 Dec 2021

Fimasartan noninferior to perindopril in older adults with essential hypertension

01 Dec 2021 by

In the treatment of older patients with essential hypertension, fimasartan alone or combined with hydrochlorothiazide demonstrates comparable safety and efficacy to perindopril monotherapy or in combination with indapamide, as shown in the results of a phase IIIb trial.

Fimasartan noninferior to perindopril in older adults with essential hypertension

01 Dec 2021

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

30 Nov 2021 by

The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

30 Nov 2021

New chest pain guideline: Takeaways & Concerns

30 Nov 2021 by

A new guideline on chest pain evaluation and diagnosis – touted as the first of its kind – is now out, reaping both praises and dissent from experts.

New chest pain guideline: Takeaways & Concerns

30 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

High factor H-related protein 1 expression ups ACVD risk

High factor H-related protein 1 expression ups ACVD risk

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

Olive oil intake may lower CVD risk among people with obesity

Olive oil intake may lower CVD risk among people with obesity

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

Milvexian prevents VTE after knee arthroplasty, bleeding risk low

Milvexian prevents VTE after knee arthroplasty, bleeding risk low

Does statin affect performance of PSA screening?

Does statin affect performance of PSA screening?

Fimasartan noninferior to perindopril in older adults with essential hypertension

Fimasartan noninferior to perindopril in older adults with essential hypertension

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor

New chest pain guideline: Takeaways & Concerns

New chest pain guideline: Takeaways & Concerns